Kyverna Therapeutics, Inc. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Kyverna Therapeutics, Inc. (KYTX) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 12.28 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-11
- Kyverna Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 12.39M shares, a 43.86% increase year-over-year.
- Kyverna Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-03-31 was 8.61M shares, a 103.73% increase year-over-year.
- Kyverna Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2024-03-31 was 4.23M shares, a 79.85% decline year-over-year.
- Kyverna Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2023-03-31 was 20.99M shares.
- Kyverna Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 10.61M shares, a 30.30% increase from fiscal 2024.
- Kyverna Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 8.14M shares, a 72.38% decline from fiscal 2023.
- Kyverna Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 29.49M shares.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month |
|---|---|---|---|---|
| 2026-06-30 | 12.28M shares 10-Q · filed 2026-08-11 | |||
| 2026-03-31 | 12.39M shares 10-Q · filed 2026-05-12 | |||
| 2025-12-31 | 10.61M shares 10-K · filed 2026-03-26 | |||
| 2025-09-30 | 10.73M shares 10-Q · filed 2025-11-12 | |||
| 2025-06-30 | 11.19M shares 10-Q · filed 2026-08-11 | |||
| 2025-03-31 | 8.61M shares 10-Q · filed 2026-05-12 | |||
| 2024-12-31 | 8.14M shares 10-K · filed 2026-03-26 | |||
| 2024-09-30 | 7.66M shares 10-Q · filed 2025-11-12 | |||
| 2024-06-30 | 4.17M shares 10-Q · filed 2025-08-12 | |||
| 2024-03-31 | 4.23M shares 10-Q · filed 2025-05-13 | |||
| 2023-12-31 | 29.49M shares 10-K · filed 2025-03-27 | |||
| 2023-09-30 | 27.89M shares 10-Q · filed 2024-11-13 | |||
| 2023-06-30 | 23.77M shares 10-Q · filed 2024-08-12 | |||
| 2023-03-31 | 20.99M shares 10-Q · filed 2024-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |